REGULATORY MANAGEMENT SOFTWARE REDUCES SUBMISSION TIME BY 80%

The only medical device RIM with integrated regulatory intelligence and AI automation.

Regulatory Management Software

TRUSTED BY LEADING COMPANIES

a red and black logo for thermo fisher scientific
a blue and white logo for acist a bracco company
a logo for a company called steris is shown
a blue and green logo for bausch + lomb
a black and white logo for helen of troy
a blue inogen logo on a white background
the word rhythm is written in blue on a white background
a medable logo that is purple and black
a black and white logo for waters tm
a truvian logo with blue dots on a white background
a blue and white logo for zimvie on a white background

What is RegDesk?

Meeting various global rules is getting more complex, and changes are happening faster. To keep up, it’s crucial to invest in an all-in-one regulatory management software. RegDesk can help.

BENEFITS OF REGDESK'S RIM PLATFORM

Prepare international applications within 1 week instead of 4 months

Reduce response time to address international inquiries from 6-8 weeks to less than 20 hours

Avoid stress and nonconformities from a Health Agency audit

Why RegDesk RIMS

With RegDesk, Regulatory Management software, enter over 120 global markets before your competitors. We make following global and local laws easy for specialized pharma and medical device companies.

This is what makes us unique

Сountries we serve

We can help you expand to 120+ markets in the world.

REGDESK REGULATORY ROUNDUP

Never miss a thing in the world of medical device regulatory compliance. The latest regulatory news and updates are always on our feed.

A Guide to Navigating Regulatory Compliance for Medical Devices

by | Jun 14, 2024 | Medical Device Regulation Resources | 0 Comments

Worldwide, medical devices are subject to strict regulations, and for good reason — they are crucial for helping health care professionals identify, treat and combat...

Medical Device Regulations in the United States

by | Jun 14, 2024 | United States,USA | 0 Comments

Medical devices are highly regulated in the United States. Since U.S. regulatory compliance for MedTech is stringent and continuously changing, staying up-to-date on...

Leveraging RIMS for Global Market Access
Leveraging RIMS Platforms for Global Market Access

by | May 29, 2024 | HSA | 0 Comments

Global market access is crucial for medical device companies looking to reach new customers, enhance brand recognition worldwide and ultimately increase revenue...

FDA on clinical trials with decentralized elements (overview)
FDA Guidance on Clinical Trials with Decentralized Elements: Overview

by | Oct 28, 2024 | FDA,United States | 0 Comments

The article highlights the key points related to specific types of clinical trials.
FDA on clinical trials with decentralized elements (overview)
FDA Guidance on Clinical Trials with Decentralized Elements: Overview

by | Oct 25, 2024 | FDA,United States | 0 Comments

The article highlights the key points related to specific types of clinical trials.
FDA on clinical trials with decentralized elements (technologies and responsibilities)
FDA Guidance on Clinical Trials with Decentralized Elements: Technologies and Responsibilities

by | Oct 25, 2024 | FDA,United States | 0 Comments

The new article describes in detail specific technologies to be used for clinical trials with decentralized elements and also clarifies the roles and responsibilities of the parties involved.
FDA Guidance on Clinical Trials with Decentralized Elements: Administration and Oversight
FDA Guidance on Clinical Trials with Decentralized Elements: Administration and Oversight

by | Oct 25, 2024 | FDA,United States | 0 Comments

The new article provides additional clarifications regarding the oversight to be conducted by the authority when it comes to clinical trials with decentralized elements, and also highlights specific aspects related to the administration of products subject to investigation.
FDA on clinical trials with decentralized elements specific aspects
FDA Guidance on Clinical Trials with Decentralized Elements: Specific Aspects

by | Oct 25, 2024 | FDA,United States | 0 Comments

The new article outlines certain specific aspects related to the existing legal framework, such as packaging, shipping, safety monitoring, as well as the use of electronic systems.
FDA on PPI in TPLC-PPI role
FDA Draft Guidance on Patient Preference Information in the TPLC: PPI Role

by | Oct 15, 2024 | FDA,United States | 0 Comments

The new article emphasizes the important role of patient preference information.
FDA on PPI in TPLC (practical considerations)
FDA Draft Guidance on Patient Preference Information in the TPLC: Practical Considerations

by | Oct 15, 2024 | FDA,United States | 0 Comments

The new article pays additional attention to the specific practical considerations pertaining to the use of patient preference information.
FDA on PPI in TPLC (FDA feedback)
FDA Draft Guidance on Patient Preference Information in the TPLC: FDA Feedback

by | Oct 15, 2024 | FDA,United States | 0 Comments

The new article highlights the aspects related to obtaining feedback from the authority in order to ensure compliance with the relevant regulatory requirements.
FDA on PPI in TPLC (additional considerations)
FDA Draft Guidance on Patient Preference Information in the TPLC: Additional Considerations

by | Oct 15, 2024 | FDA,United States | 0 Comments

The new article is dedicated to additional considerations to be taken into account when using patient preference information associated with medical devices intended to be marketed and used in the US.